Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

tions, risks that the Chemical, Manufacturing and Controls section of Discovery's New Drug Application will not satisfy the FDA, risks relating to the ability of Discovery or Discovery's third party manufacturers and development partners to manufacture or provide Discovery with adequate supplies of drug substances and expertise for completion of any of Discovery's clinical studies, risks related to the ability of Discovery and its collaborators to develop, manufacture and successfully commercialize products that combine Discovery's drug products with innovative aerosolization technologies, risks relating to drug manufacturing by Discovery, risks relating to the significant, time-consuming and costly research, development, pre-clinical studies, clinical testing and regulatory approval process for any products that Discovery may develop independently or with Discovery's collaboration arrangements, risks relating to the development by other companies of competing therapies and/or technologies, risks relating to reimbursement and health care reform, and risks relating to securities, product liability and other litigation. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising earlier trial results. Data obtained from tests are susceptible to varying interpretations, which may delay, limit or prevent regulatory approval. Those associated risks and others are further described in Discovery's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

Company Contact: Lisa Caperelli, Investor Relations 215-488-9413


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:3/5/2015)... 5, 2015 BioLineRx (NASDAQ: ... dedicated to identifying, in-licensing and developing promising therapeutic ... underwritten public offering of American Depositary Shares ("ADSs"), ... All of the ADSs in the offering are ... JMP Securities is acting as sole book-running manager ...
(Date:3/5/2015)... Deutschland, 5. März 2015  Die amerikanische ... deutsche biopharmazeutische Unternehmen CureVac geben heute bekannt, ... Millionen US-Dollar) in CureVac investiert. CureVac ist ... Messenger-RNA (mRNA). Auf Basis dieses Moleküls entwickelt ... Krankheiten und zum Schutz vor Infektionskrankheiten. ...
(Date:3/5/2015)... March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... quarter ended January 31, 2015 on Thursday, March 12 before ... the results at 11:00 AM ET. To ... to 10 minutes before the beginning of the call. If ... call will be available from Thursday, March 12, 2015 through ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... BEIJING , July 12 ... "Company") (NYSE: CCM ), the,operator of the largest ... today announced that effective as of July 1, 2010 ... for the operation of Chang,An,Hospital,s cancer treatment facilities by acquiring ...
... weeks beginning July 12 , ecoSTORE USA ,s elite team of Ecovisors will give ... select Duane Reade drug stores in New York City .  Ecovisors will also ... Nasty Ch e mic a l s™ ... , , ecoSTORE ...
Cached Medicine Technology:Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 2Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 3Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 4Ecovisors to Advise Duane Reade Shoppers 2Ecovisors to Advise Duane Reade Shoppers 3
(Date:3/6/2015)... La (PRWEB) March 06, 2015 Many ... function despite medical therapy. If you (or someone you ... to knee osteoarthritis, you may be interested in the ... Covington Orthopedic announced today that he is one of ... Cytori Therapeutics to begin enrolling subjects as part of ...
(Date:3/6/2015)... 06, 2015 Magellan Rx Management’s 2014 ... source for key trends and statistics on one of ... Executives from Magellan Rx Management will discuss key findings ... Your Hidden Specialty Drug Spend,” a complimentary March 19 ... , Specialty drug spend makes up more than a ...
(Date:3/6/2015)... March 06, 2015 Utilizing the latest ... rapidly reach their ideal weight has enabled Diet Doc ... to their already impressive collection of fat loss enhancement ... clients special promotions and savings to help people throughout ... This promotion is especially appealing to new clients ...
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 Yisrayl ... in Abilene, Texas, has released a new publication explaining ... working. , The article titled “Microorganisms Do ... document explaining how tiny microorganisms were created and designed ... is aware of some of the functions of these ...
(Date:3/6/2015)... March 06, 2015 You Wealth ... created a unique ‘energy’ experiment to determine if ... , After quick ‘5 -7 minute’ remote ... 150+ countries reported their life improving - often ... positive results. , According to research, respondents saw ...
Breaking Medicine News(10 mins):Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2
... on Certain Products Expanded to Retail LevelST. LOUIS, Feb. 3 ... KVa ; KVb), is issuing a voluntary ... on certain products. The recall on the products listed ... is now being expanded to the retail level. The ...
... for Improving Cancer Care Access, Efficiency and Quality; ... NetworkWASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- The ... one of the nation,s largest cancer treatment and ... adopted its Principles for Reforming Cancer Care, designed ...
... 2009) Green tea products have become regarded as ... of its benefit against a variety of diseases, including ... green tea may counteract the anticancer effects of one ... be contraindicated for patients taking this medicine to ensure its ...
... to popular assumptions about the health benefits of green ... have found that the widely used supplement renders a ... cell lymphoma completely ineffective in treating cancer. , ... tea extract (GTE) called EGCG destroys any anticancer activity ...
... 3 VirtualScopics, Inc.,(Nasdaq: VSCP ), a ... that Mr. Jeff Markin, the company,s chief executive,officer, will ... Annual,BIO CEO & Investor Conference at the Waldorf Astoria ... Tuesday, February 10, 2009 at 3:45pm EST. , ...
... prescribed physical activity, survey finds, , , TUESDAY, Feb. 3 (HealthDay ... with and alleviate chronic neck and back pain, a new ... as often as they should. , Less than half ... had seen a physician, chiropractor or physical therapist in the ...
Cached Medicine News:Health News:ETHEX Corporation Issues Voluntary Nationwide Recall 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 3Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3Health News:USC study finds that green tea blocks benefits of cancer drug 2Health News:VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference 2Health News:Are We Exercising Pain Away? Not So Much. 2
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
... Amsco 3085 SP Surgical Table provides state-of-the-art ... now be networked with the HERMES Control ... Stryker Endoscopy) to allow the surgeon direct ... surgeon uses either simple voice commands or ...
... The ASC 2000 is ... care table, meeting good manufacturing ... regulatory requirements. It provides electro-hydraulic ... accessories for all ambulatory surgical ...
... The hands play an important part ... traumatic impairments and rheumatic changes can cause ... developing of the finger-joint prostheses was to ... reproduce the natural function as nearly possible.,The ...
Medicine Products: